Research
PT-141
A cyclic seven-amino-acid peptide, and an active metabolite of Melanotan-2 developed as a compound in its own right.
Available in the catalogue
Supplied as research material. Sizes and pricing are on the product page. Availability is not a statement about what a compound does.
What is being investigated
Directions the published work points at, and how far each has actually got. These are open questions, not established effects: most of what looks promising in cells does not replicate in animals, and most of what works in animals does not work in people. Nothing here is a claim about what this compound does for anyone.
- Hypoactive sexual desire disorder in premenopausal women
The indication it is authorised in, on two randomised phase 3 trials across more than a thousand participants. What was authorised is a specific medicine, not this material.
Human trials
- Erectile dysfunction
An earlier intranasal programme in men, discontinued after blood pressure rises were observed. That is the reason the compound went the direction it did, and it belongs beside the approval above.
Human trials
- A central rather than vascular mechanism
What separates it from the PDE5 inhibitors: it acts at MC4R in the central nervous system rather than on vascular tissue, so the pathway is neural. Established in animal work.
Animal studies
Published research
Every reference below was checked against the published record before being listed, with the model each study used.
- Kingsberg et al. (2019)Obstetrics & Gynecology · 134(5):899–908
Reported efficacy and safety across 1,267 premenopausal women with hypoactive sexual desire disorder.
human, two randomised phase 3 trials (RECONNECT) Source
Further reading
Longer articles on handling, analysis and what the published work reports.
- PT-141 (bremelanotide): what the research says
Approved in the US as Vyleesi, with two phase 3 trials and a published safety programme. The mechanism is neural at MC4R, not vascular like PDE5 inhibitors.
- How to store research peptides
Lyophilised peptides at -20°C, reconstituted at 2–8°C, ambient in transit. Why the dry cake tolerates shipping, and what actually degrades a vial.
- Peptide shelf life and stability
How long lyophilised and reconstituted peptides keep, and the four things that shorten it: temperature, moisture, light and oxidation. Storage figures included.
- How to reconstitute lyophilised peptides
How to reconstitute a lyophilised peptide with bacteriostatic water without damaging it: why you run the liquid down the vial wall and never shake it.